We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of RG-012 in Subjects With Alport Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03373786
Recruitment Status : Completed
First Posted : December 14, 2017
Last Update Posted : April 25, 2022
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.

Condition or disease Intervention/treatment Phase
Alport Syndrome Drug: RG012 Phase 1

Detailed Description:
This is a Phase 1, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome. During this open-label study, all eligible subjects will receive RG-012. The study consists of two parts (Part A and Part B). During Part A, half of the participants will receive a single dose of RG-012 and half will receive 4 doses of RG-012 (one dose every other week for 6 weeks). All subjects will undergo two renal biopsies, one before and one after receiving RG-012, to assess the effect of RG-012 on the kidney. After completing Part A, subjects will be able to enter Part B of the study. During Part B, all subjects will receive RG-012 every other week for 48 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome
Actual Study Start Date : December 22, 2017
Actual Primary Completion Date : May 20, 2019
Actual Study Completion Date : May 20, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RG-012 Single Dose
1.5 mg/kg RG012 subcutaneous injection
Drug: RG012
RG012 in 0.3% sodium chloride

Experimental: RG012 Every Other Week
1.5 mg/kg RG012 subcutaneous injections every other week
Drug: RG012
RG012 in 0.3% sodium chloride

Primary Outcome Measures :
  1. Safety - Adverse Events [ Time Frame: 8 weeks ]
    Incidence and severity of adverse events

  2. Effect of RG-012 on renal microRNA-21 (miR-21) [ Time Frame: 8 weeks ]
    Change in miR-21 expression in renal tissue

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) parameter - Cmax [ Time Frame: 8 weeks ]
    Maximum observed plasma concentration

  2. Pharmacokinetic (PK) parameter - Tmax [ Time Frame: 8 weeks ]
    Time to maximum observed plasma concentration

  3. Pharmacokinetic (PK) parameter - AUC [ Time Frame: 8 weeks ]
    Area under the plasma concentration vs. time curve

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females, ages 18 to 65 years
  2. Confirmed diagnosis of Alport syndrome
  3. eGFR between 40 and 90 mL/min/1.73m2
  4. Proteinuria of at least 300 mg protein/g creatinine
  5. For subjects taking an ACE inhibitor or an ARB, the dosing regimen should be stable for at least 30 days prior to screening
  6. Willing to comply with contraception requirements

Exclusion Criteria:

  1. Causes of chronic kidney disease aside from Alport syndrome (such as diabetic nephropathy, hypertensive nephropathy, lupus nephritis, or IgA nephropathy)
  2. End stage renal disease (ESRD) as evidenced by ongoing dialysis therapy or history of renal transportation
  3. Any other condition that may pose a risk to the subject's safety and well-being
  4. Female subjects who are pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373786

Layout table for location information
United States, California
La Mesa, California, United States, 91942
Academic Medical Research Institute
Los Angeles, California, United States, 90022
Apex Research of Riverside
Riverside, California, United States, 92505
United States, Florida
Eminence Medical & Clinical Research
Tampa, Florida, United States, 33604
United States, Texas
Houston Nephrology Research
Cypress, Texas, United States, 77429
United States, Utah
Utah Kidney Research Institute
Salt Lake City, Utah, United States, 84107
United States, Wisconsin
Allegiance Research Specialists, LLC
Wauwatosa, Wisconsin, United States, 53226
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Clinical Sciences & Operations, M.D. Sanofi
Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT03373786    
Other Study ID Numbers: PDY16327
RG012-06 ( Other Identifier: Regulus Therapeutics Inc. )
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: April 25, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
Kidney disease
Hereditary kidney disease
Hereditary nephritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Nephritis, Hereditary
Pathologic Processes
Urogenital Abnormalities
Kidney Diseases
Urologic Diseases
Congenital Abnormalities
Collagen Diseases
Connective Tissue Diseases